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EDITORIALMicrobiota Alterations in Inﬂammatory Bowel Diseases:
From Correlation to Causalitynﬂammatory bowel disease (IBD) is a group of chronicIintestinal inﬂammatory disorders, mainly comprising
Crohn’s disease (CD) and ulcerative colitis, which together
affect 1.4 million people in the United States and 2.2 million
people in Europe.1 Many studies have shown the presence
of an altered intestinal microbiota composition in IBD
patients, as well as in mouse models of chronic intestinal
inﬂammation (such as Toll-like receptor 5-/- and interleukin
10-/- models).2–6 However, as stated by the authors of an
exciting article published in the current issue of Cellular and
Molecular Gastroenterology and Hepatology, “it remains
unclear whether IBD-associated gut dysbiosis contributes to
disease pathogenesis or is merely secondary to intestinal
inﬂammation.”7 Although many studies have described
alterations of microbiota composition, localization, tran-
scriptome, and/or proinﬂammatory potential during intes-
tinal inﬂammation, these observations could be consecutive
to the intestinal inﬂammation instead of being a primary
causative hit that contributes to the appearance of
inﬂammation.
In their study, Nagao-Kitamoto et al7 aimed to decipher
whether altered microbiota observed in IBD patients play a
primary role in intestinal inﬂammation or rather are a
consequence of inﬂammation. They used the approach of
transferring IBD-associated microbiota to germ-free recip-
ient mice, and then analyzed microbiota composition, fecal
metabolome, and intestinal transcriptome. By using this
humanized gnotobiotic mouse system followed by a multi-
layered approach, the authors conﬁrmed that the altered
microbiota from IBD patients was transferred efﬁciently to
recipient germ-free animals, and was associated with an
increased proinﬂammatory potential (increases in bioactive
ﬂagellin), an altered metabolome, and an increased
expression of multiple proinﬂammatory cytokines by the
host. These ﬁndings show that altered microbiota from CD
and ulcerative colitis patients seem sufﬁcient to alter the
intestinal environment in a way that favors the appearance
of inﬂammation.
Next, the study addressed a very important point using
this humanized gnotobiotic mouse model: are those changes
in microbiota composition sufﬁcient to drive disease? The
authors importantly found that microbiota from CD patients
drove intestinal inﬂammation when transferred to geneti-
cally susceptible interleukin 10-/- mice, showing that an
altered microbiota composition from IBD patients is sufﬁ-
cient to drive intestinal inﬂammation in genetically sus-
ceptible hosts. However, it remains possible that the altered
gut microbiota in IBD patients is only a second hit—a
consequence of intestinal inﬂammation rather than a
primary cause of the disease. For example, IBD-associatedCellumicrobiota is well characterized to be more proin-
ﬂammatory, with, for example, the presence of pathobionts
and an expansion of Enterobacteriaceae as consequences of
intestinal inﬂammation,8,9 both of which are able to drive
intestinal inﬂammation in recipient mice even if they were
not the cause of the disease in the ﬁrst place.4,5
To conclude, the article by Nagao-Kitamoto et al7 not
only reported alterations of microbiota composition in IBD
patients, but elegantly identiﬁed the functional conse-
quences of such altered community by using a humanized
mouse model. This study beneﬁted from a recent technical
development that is beginning to impact this area of
research: positive-pressure individual ventilated cages
(IVCs).10,11 Most of the studies currently using germ-free
animals use isolators, where all the animals are housed
inside a single unit and harbor the same microbiota (mon-
ocolonized, humanized, and so forth). The use of IVCs
dramatically facilitates the use of germ-free animals for such
experiments because it allows multiple conditions to be
compared in parallel.7 The IVC system thus provides great
improvement for the simultaneous analysis of multiple
groups, and will facilitate the understanding of the role
played by the gut microbiota in the development of intes-
tinal inﬂammation, carcinogenesis, and many other diseases
with a microbiota component.
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